Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Total Current Liabilities: 2022-2025

Historic Total Current Liabilities for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $56.5 million.

  • Day One Biopharmaceuticals' Total Current Liabilities rose 42.07% to $56.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.5 million, marking a year-over-year increase of 42.07%. This contributed to the annual value of $73.5 million for FY2024, which is 148.92% up from last year.
  • Day One Biopharmaceuticals' Total Current Liabilities amounted to $56.5 million in Q3 2025, which was up 10.24% from $51.2 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Total Current Liabilities high stood at $93.7 million for Q2 2024, and its period low was $8.2 million during Q1 2022.
  • Moreover, its 3-year median value for Total Current Liabilities was $39.7 million (2024), whereas its average is $44.9 million.
  • In the last 5 years, Day One Biopharmaceuticals' Total Current Liabilities soared by 282.29% in 2024 and then tumbled by 45.34% in 2025.
  • Quarterly analysis of 4 years shows Day One Biopharmaceuticals' Total Current Liabilities stood at $16.6 million in 2022, then soared by 77.60% to $29.5 million in 2023, then spiked by 148.92% to $73.5 million in 2024, then skyrocketed by 42.07% to $56.5 million in 2025.
  • Its last three reported values are $56.5 million in Q3 2025, $51.2 million for Q2 2025, and $47.9 million during Q1 2025.